GeoVax Posts Financials for Q1 2017 and Provides Update

GeoVax Labs (OTCQB:GOVX) released their financial results for the first quarter of 2017 and gave updates on the state of its various vaccines.

As quoted in the press release:
Robert T. McNally, Ph.D., GeoVax’s President and CEO, commented, “During the first quarter of 2017, GeoVax made progress in each of our vaccine development programs. Our MVA-VLP vaccine platform continues to prove itself through our expanding product portfolio, our growing list of high-quality corporate and academic collaborators, and promising preclinical and clinical testing results. Recent highlights include:
We reported very impressive preclinical results (100% protection) for our Zika vaccine from a highly rigorous lethal challenge model conducted by the Centers for Disease Control and Prevention (CDC). Importantly, our approach to a Zika vaccine is unique as it is based on the non-structural-1 protein of the Zika virus and thus will avoid the Antibody Dependent Enhancement (ADE) of infection safety issue, which is a concern for other Zika vaccines under development.
We initiated a new clinical trial for our preventive clade B HIV vaccine for the developed world. This trial is being fully funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). And we continued our work under a $7.8 million NIAID contract for production of the DNA component of our vaccine intended for later stage clinical trials.
We were awarded a $658,000 grant from NIAID to continue our work toward a clade C HIV vaccine for the developing world.

Click here to read the full press release.

Source: www.marketwired.com